Immix Biopharma, Inc. (NASDAQ: IMMX) is a Healthcare company (Biotechnology) with a market capitalization of $603M. The Maz Rating grades it against the other companies in its sector.
Immix Biopharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.20, Immix Biopharma, Inc. trades at 1.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -24.9%, return on invested capital of -14.9% and a free cash flow yield of -7.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 33.72. Over the past 52 weeks the share price ranged from $3.78 to $15.10, with a beta of 0.11.
Immix Biopharma, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.